Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › encorafenib

encorafenib

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of encorafenib

9 trials tracked of encorafenib: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 539 citations.

9Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 5 Phase 1 2 Other / NA 1
  1. Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer Completed · 539 cited
  2. Phase 2 Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer Completed
  3. Phase 2 A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. Completed
  4. Phase 2 A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers Completed
  5. Phase 2 An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer Completed
  6. Phase 2 Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain Completed
Show 3 more trials
  1. Phase 1 Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors Completed
  2. Phase 1 Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors Completed
  3. N/A Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Encorafenib plus binimetinib maintains quality of life in BRAF V600E-mutated thyroid cancer
Oncology Phase II
Encorafenib plus binimetinib maintains quality of life in BRAF V600E-mutated thyroid cancer Can new drugs help advanced thyroid cancer patients keep their daily life stable?
An uncontrolled phase 2 trial of 22 patients with BRAF V600E-mutated thyroid cancer found encorafenib plus binimetinib was associated with g…
A new drug combination helped advanced thyroid cancer patients maintain daily life stability without worsening their quality of life during …
Apr 9, 2026
Retrospective analysis identifies molecular correlates of benefit with encorafenib-based therapy in BRAF-mutant melanoma
Dermatology RCT
Retrospective analysis identifies molecular correlates of benefit with encorafenib-based therapy in BRAF-mutant melanoma Melanoma study finds tumor genetics and immune markers may predict treatment benefit
A retrospective exploratory analysis of the phase III COLUMBUS trial in 921 patients with BRAF V600E/K-mutant advanced melanoma found that s…
Patients with advanced melanoma who have higher tumor mutational burden or signs of immune system activity gain the most survival benefit fr…
Apr 4, 2026